COPY
COPY

DOBE LAW GROUP, LLC

From: Chris Aniedobe, Esq.
Direct Phone: 301.982.0153
Email: Chris@DobeLawGroup.com

Dobe Law Group, LLC
7207 Hanover Parkway.
Suite C/D
Greenbelt, MD 20770
301.982.0152
Fax 301.982.0154

November 19, 2007

ATTN: Certificate of Correction Branch
Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Re: U.S. Patent No.: 7,244,431
Issue Date: 07/17/2007
Application No. 10/026,911
For: *Allergy Vaccines and Their Preparation*
Inventor(s): FOCKE, et al.
Attorney Docket No.: 966927.00005

Sir:

The following documents are forwarded herewith for appropriate action by the U.S. Patent and Trademark Office:

1. Request for Expedited Issuance of Certificate of Correction under 37 C.F.R. § 1.322;
2. One of Certificate of Correction Form PTO-1050;
3. Copy of Response and Amendments Under 37 CFR 1.116 filed Jan. 30, 2007;
4. One Copy of Date Stamped Postcard dated Jan. 30, 2007;
5. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier.

Respectfully submitted,
Dobe Law Group, LLC

Christopher E. Aniedobe, Esq.
Reg. No. 48,293

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Name of Patentee. FOCKE, et al.	Art Unit: 1761
Patent No. 7,244,431	Examiner: Szperka, Michael E.
Issued: July 17, 2007	Atty. Docket: 966927.00005
Title of Invention: *Allergy Vaccines and Their Preparation*	

ATTN: Certificate of Correction Branch
Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Request for Expedited Issuance of Certificate of Correction under 37 C.F.R. § 1.322

Pursuant to 35 U.S.C. § 254 and 37 C.F.R. § 1.322, this is an expedited request for the issuance of a Certificate of Correction in the above-identified patent. One copy of PTO Form 1050 is enclosed. The complete Certificate of Correction involves one (1) page.

As shown in the enclosed copy of amendments and remarks under 37 CFR 1.116, filed on January 30, 2006, there is a clerical error in publishing part (e) of Application claim 38, now Patent Claim 1, in that Application claim 38 recited "(e) does not induce an IGE-mediate allergic reaction..."; however, Patent Claim 1 recited, --(e) does not induce an IRE-mediated allergic reaction ...-- Correction is duly requested.

Being the mistake of the Patent and Trademark Office, it is not believed that the fee of $100.00 under 37 C.F.R. § 1.20(a) is due. If any fees are needed, however, authorization is hereby given to charge any fees due in connection with the filing of this request to Deposit Account No. **50-4336**.

Expedited issuance of the Certificate of Correction containing the correction is respectfully requested.

Respectfully submitted,
Dobe Law Group, LLC

By: _____
Christopher E. Aniedobe, Esq
Reg. No. 48,293

Dated: 11/19/2007
Dobe Law Group, LLC
7207 Hanover Parkway, Ste C/D
Greenbelt, MD, 20770

NOV 26 2007

PTO/SB/44 (09-07)
Approved for use through 08/31/2010. OMB 0651-0033
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,244,431
APPLICATION NO.: 10/026,911
ISSUE DATE : July 17, 2007
INVENTOR(S) : FOCKE, Margarete et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Claims,
Column 20,
Line 33, "IRE-mediated" should read --"IGE-mediated--

MAILING ADDRESS OF SENDER (Please do not use customer number below):
Dobe Law Group,LLC
7207 Hanover Pkwy Ste C/D
Greenbelt, MD 20770

NOV 26 2007

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Focke et al.

Art Unit: 1644

Appl. No: 10/026,911

Examiner: Szperka, Michael Edward

Filed: December 27, 2001

Atty. Docket: 966927.00005

(Old S & H No. 0273-0005)

For: Allergy Vaccines and Their Preparation

RESPONSE AND AMENDMENTS UNDER 37 C.F.R. § 1.116

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Office Action dated October 30, 2006, Applicants submit the following Amendments and Remarks.

Response being due on or before January 30, 2007, it is believed that no extension of time for response is necessary. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims are hereby authorized to be charged to our Deposit Account No. 50-0622.

Applicants respectfully request that the above-captioned application be amended as indicated below.

In the Claims:

Please cancel claims 1-4, 9, 34 – 37, and amend claim 38, as shown in the following listing of the entire claims in the Application.

1.- 4. (canceled)

5. – 8. (canceled)

9. (canceled)

10 – 13. (canceled).

14. (withdrawn) A method for preparing a pharmaceutical composition comprising:

a) determining which amino acids of a given allergenic protein are solvent-exposed on the surface of the allergenic protein;

b) preparing a peptide having a length of 8 to 50 amino acids, wherein at least three preferably consecutive amino acids of the peptide are identical to at least three solvent-exposed amino acids of the allergenic protein which appear in close vicinity on the molecular surface of the allergenic protein; and

c) optionally admixing the peptide with a pharmaceutically acceptable carrier or diluent.

15. (withdrawn) A method according to claim 14, wherein said at least three solvent-exposed amino acids appear on the molecular surface of the allergenic protein within a surface patch of approximately 500 square Angström.

16. (withdrawn) A method according to claim 14, wherein at least five consecutive amino acids of the peptide are identical to at least five consecutive solvent-exposed amino acids of the allergenic protein.

17. (withdrawn) A method according to claim 14, further comprising adding an adjuvant.

18. (withdrawn) A method according to claim 14, wherein all amino acids of the peptide except one are identical to the amino acids of an amino acid sequence which is part of the allergenic protein amino acid sequence.

19. (withdrawn) A method according to claim 18, wherein the one amino acid which deviates from the amino acid sequence of the allergenic protein is the N-terminal or C-terminal amino acid of the peptide amino acid sequence.

20. (withdrawn) A method according to claim 14, wherein the amino acid sequence of the peptide is identical to an amino acid sequence which is part of the allergenic protein amino acid sequence.

21. (withdrawn) A method according to claim 14, wherein the allergenic protein is the birch pollen allergen Bet v 1.

22. (withdrawn) A method according to claim 14, wherein the peptide amino acid sequence comprises at least the N-terminal or C-terminal five amino acids of the allergenic protein amino acid sequence.

23. (withdrawn) A method according to claim 14, wherein the solvent-exposed amino acids of the allergenic protein are determined by determining the hydrophilicity profile of the allergenic protein.

24. (withdrawn) A method according to claim 14, wherein the solvent-exposed amino acids of the allergenic protein are determined from the three-dimensional structure of the allergenic protein.

25 – 27 (canceled).

28. (withdrawn) A method for treating an allergic disease, comprising: administering to a patient in need thereof the pharmaceutical composition of claim 1.

29. (withdrawn) A method according to claim 28, wherein the at least three solvent-exposed amino acids appear on the molecular surface of the allergenic protein within a surface patch of approximately 500 square Angström.

30. (withdrawn) A method according to claim 28, wherein at least five consecutive amino acids of the peptide are identical to at least five consecutive solvent-exposed amino acids of the allergenic protein.

31. (withdrawn) A method according to claim 28, wherein the peptide, upon administration, is capable of inducing IgG antibodies which react with the allergenic protein.

32. (withdrawn) A method according to claim 31, wherein the induced IgG antibodies can reduce or prevent binding of IgE antibodies to the allergenic protein.

33. (withdrawn) A method according to claim 28, wherein the peptide, upon administration, does not induce a significant IgE response.

34. – 37. (canceled)

38. (currently amended). A pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a peptide for use as immunotherapeutic agent capable of inducing IgG antibodies response to allergenic proteins without inducing IgE-mediated allergic reaction wherein the peptide:

a) has an amino acid sequence obtained from the birch pollen allergen Bet v 1;

b) has a length of at least 8 and no more than 50 amino acids;

c) has at least three consecutive amino acids identical to at least three solvent-exposed amino acids of an allergenic protein which appear in close vicinity on the molecular surface of the allergenic protein;

d) is upon administration capable of inducing IgG antibodies to the allergenic protein and

[illegible] 26 2007

e) does not induce an IgE-mediated allergic reaction; and

~~The pharmaceutical composition according to claim 1,~~ wherein the peptide is any one of Seq. ID. Nos. 1 to 6.

REMARKS

Reconsideration and allowance of the present application is respectfully requested in view of the foregoing amendments and the following additional remarks which have addressed all the issues raised in the October 30, 2006, Office Action or otherwise have rendered them moot.

Claim 38 was objected to as being dependent upon a rejected independent claim but would be otherwise allowable if rewritten in independent form including all the limitations of the independent claim and any intervening claims. Applicants have done just that and respectfully ask the Examiner to send the application to issue. Applicants have elected to pursue all or some of the remaining claims in a continuation application to be filed later.

CONCLUSION

All of the stated grounds for rejection have been properly traversed, accommodated, or rendered moot. Applicants therefore respectfully request that the Examiner reconsider all presently outstanding rejections and that they be withdrawn and the claims allowed to issue. If the Examiner believes, for any reason, that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at the number provided.

Respectfully submitted,

REED SMITH, LLP

Date: 01/30/2007

By: _____

Christopher E. Aniedobe
Reg. No. 48, 293

3110 Fairview Park Dr.
Suite 1400
Falls Church, VA 22042
(703) 641-4203

32256
PATENT TRADEMARK OFFICE

JAN 26 2007

Applicant:	Focke, et al.	Docket	966927.00005
App. Serial No:	10/026,911	Attorney:	Toni-Junell Herbert/TJY/sch
Filed:	December 27, 2001		REED SMITH, LLP
For:	Allergy Vaccines and Their Preparation		

When receipt stamp is placed hereon, the USPTO acknowledges receipt of the following:

1. Transmittal Letter to the United States Patent and Trademark Office;
2. Response and Amendments Under 37 C.F.R. § 1.116; and
3. One (1) Return postcard.

NOV 2 6 2007